natgillin/translations-raw huggingface dataset:
• Respiratory infections such as chest infection, flu, sore throat, runny nose, blocked nose, sneezing, feeling of pressure or pain in the cheeks or forehead with or without fever (pneumonia, bronchitis, influenza, sinusitis, rhinitis, pharyngitis, tonsilitis, nasopharyngitis, upper respiratory tract infection). 
• Respiratorne infekcije kao što su infekcija dišnih puteva, gripa, grlobolja, curenje nosa, začepljen nos, kihanje, osjećaj pritiska ili boli u obrazima ili čelu s vrućicom ili bez nje (pneumonija, bronhitis, influenca, sinusitis, rinitis, faringitis, tonzilitis, nazofaringitis, infekcija gornjeg dijela dišnog sustava).
It is unknown whether canakinumab is excreted in human milk. 
Nije poznato izlučuje li se kanakinumab u majčino mlijeko u ljudi.
Predicted canakinumab steady state exposures at a dose level of 4 mg/kg (maximum 300 mg) in patients over the age of 20 years were comparable to those in SJIA patients younger than 20 years of age. 
Predviđeno izlaganje kanakinumabu u stanju dinamičke ravnoteže pri doziranju od 4 mg/kg (maksimum 300 mg) u bolesnika starijih od 20 godina bilo je usporedivo s onim u bolesnika sa SJIA-om mlađih od 20 godina.
For CAPS, TRAPS, HIDS/MKD, FMF and Still's disease, the treatment should be initiated and supervised by a specialist physician experienced in the diagnosis and treatment of the relevant indication. 
Za CAPS, TRAPS, HIDS/MKD, FMF i Stillovu bolest, liječenje mora započeti i nadzirati liječnik specijalist s iskustvom u dijagnosticiranju i liječenju relevantne indikacije.
Ilaris blocks the activity of IL-1 beta, which may improve the signs and symptoms of Still's disease. 
Ilaris blokira aktivnosti IL-1 beta, što može ublažiti znakove i simptome Stillove bolesti.
In the overall SJIA programme, transient decreased white blood cell (WBC) counts ≤ 0.8 x LLN were reported in 33 patients (16.5%). 
U cjelokupnom programu za SJIA-u prolazno snižene razine broja leukocita (Lkc) ≤ 0,8 x DGN bile su zabilježene u 33 bolesnika (16,5%).
Slowly pull the syringe plunger up to the correct mark (amount to be given as per healthcare provider's instructions), filling the syringe with Ilaris solution. 
Polako povucite klip štrcaljke do odgovarajuće oznake (za količinu koja će se primijeniti prema uputama zdravstvenog djelatnika), tako da se štrcaljka napuni Ilaris otopinom.
- Still's disease including adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) - Gouty arthritis 
- Stillova bolest uključujući Stillovu bolest odrasle dobi (SBOD) i sistemski juvenilni idiopatski artritis (SJIA) - urični artritis
One patient had resolution of index flare by day 15 after receiving one single dose of canakinumab 2 mg/kg, but discontinued treatment after this first dose due to serious adverse events (pancytopenia and hepatic failure). 
U jednog se bolesnika razbuktavanje osnovne bolesti povuklo do 15. dana nakon jednokratne doze kanakinumaba od 2 mg/kg, ali bolesnik je prekinuo liječenje nakon te prve doze zbog ozbiljnih nuspojava (pancitopenija i zatajenje jetre).
Overall, there were no clinically meaningful differences in the safety and tolerability profile of canakinumab in paediatric patients compared to the overall CAPS population (comprised of adult and paediatric patients, N=211), including the overall frequency and severity of infectious episodes. 
Općenito nije bilo klinički relevantnih razlika u profilu sigurnosti i podnošljivosti kanakinumaba kod pedijatrijskih bolesnika u usporedbi s cjelokupnom populacijom bolesnika s CAPS-om (koju čine odrasli i pedijatrijski bolesnici, N=211), što uključuje cjelokupnu učestalost i težinu infektivnih epizoda.
This is administered every four weeks as a single dose via subcutaneous injection. 
Jedna doza se primjenjuje svaka četiri tjedna kao supkutana injekcija.
Study G2305 was a randomised, double-blind, placebo-controlled, 4-week study assessing the shortterm efficacy of canakinumab in 84 patients randomised to receive a single dose of 4 mg/kg (up to 300 mg) canakinumab or placebo. 
Ispitivanje G2305 bilo je randomizirano, dvostruko slijepo, placebom kontrolirano, 4-tjedno ispitivanje kojim se ocjenjivala kratkoročna djelotvornost kanakinumaba u 84 bolesnika randomiziranih na primanje jednokratne doze od 4 mg/kg (do 300 mg) kanakinumaba ili placeba.
No dose adjustment is needed in patients with renal impairment. 
Nije potrebno prilagođavati dozu kod bolesnika s oštećenjem bubrega.
TRAPS n=number of responders; N=number of evaluable patients * indicates statistical significance (one-sided) at the 0.025 level based on Fisher exact test **Indicates statistical significance (one-sided) at the 0.025 level based on the logistic regression model with treatment group and baseline PGA, CRP or SAA respectively, as explanatory variables for each cohort 
TRAPS n=broj bolesnika s odgovorom; N=broj bolesnika koje je bilo moguće ocijeniti * označava statističku značajnost (jednostrano) pri 0,025 na temelju Fisherovog egzaktnog testa ** označava statističku značajnost (jednostrano) pri 0,025 na temelju modela logističke regresije s terapijskom skupinom odnosno početnim PGA-om, CRP-om ili SAA-om, kao eksplanatornim varijablama za svaku kohortu
What Ilaris is 
Što je Ilaris
Ilaris treatment may give you a spinning sensation (dizziness or vertigo) or intense tiredness (asthenia). 
Liječenje Ilarisom može Vam uzrokovati osjećaj vrtnje (omaglica ili vrtoglavica) ili intenzivan umor (asteniju).
The peak serum canakinumab concentration (Cmax) occurred approximately 7 days following single subcutaneous administration of 150 mg in adult CAPS patients. 
Do vršne koncentracije kanakinumaba u serumu (Cmax) došlo je otprilike 7 dana nakon jednokratne supkutane primjene 150 mg u odraslih bolesnika s CAPS-om.
Unable to use both NSAIDs and colchicine; on ULT N=62 Treatment of gouty arthritis attacks as measured by pain intensity (VAS) at 72 h Least Squares mean estimated difference to triamcinolone acetonide CI p-value, 1-sided p < 0.0001* 
Ne mogu koristiti ni NSAILove niti kolhicin; na ULT-u N=62 Liječenje napada uričnog artritisa mjereno intenzitetom boli (VAS) nakon 72 h Srednja vrijednost razlike procijenjena metodom najmanjih kvadrata u odnosu na triamcinolon acetonid CI p-vrijednost, jednostrana p<0,0001*
How long to use Ilaris 
Koliko dugo primjenjivati Ilaris
150 mg or 2 mg/kg 
150 mg ili 2 mg/kg
The solution is a clear to opalescent liquid. 
Otopina je bistra do opalescentna tekućina.
Slowly pull the syringe plunger up to the correct mark (amount to be given), filling the syringe with Ilaris solution. 
Polako povucite klip štrcaljke do odgovarajuće oznake (za količinu koju treba primijeniti), tako da se štrcaljka napuni Ilaris otopinom.
Isolated cases of unusual or opportunistic infections (including aspergillosis, atypical mycobacterial infections, herpes zoster) have been reported during canakinumab treatment. 
Tijekom liječenja kanakinumabom zabilježeni su izolirani slučajevi neuobičajenih ili oportunističkih infekcija (uključujući aspergilozu, atipične mikobakterijske infekcije, herpes zoster).
Read these instructions all the way through before beginning. 
Prije nego počnete pročitajte u cijelosti ove upute.
Candida - vaginal yeast infection (vulvovaginal candidiasis). 
Gljivična infekcija rodnice kandidom (vulvovaginalna kandidijaza).
A pro-inflammatory protein called IL-1 beta plays an important role in Still's disease inflammation. 
Proinflamatorni protein koji se zove IL-1 beta igra važnu ulogu u upalnim procesima kod Stillove bolesti.
After repeated administration of 4 mg/kg every 4 weeks the accumulation ratio of canakinumab was 1.6 fold in SJIA patients. 
Nakon opetovane primjene 4 mg/kg svaka 4 tjedna omjer akumulacije kanakinumaba bio je 1,6 puta veći u bolesnika sa SJIA-om.
Triglycerides 
Trigliceridi
Women should use effective contraceptives during treatment with canakinumab and for up to 3 months after the last dose. 
Žene reproduktivne dobi / Kontracepcija u muškaraca i žena Žene moraju koristiti učinkovitu kontracepciju tijekom liječenja kanakinumabom te do 3 mjeseca nakon posljednje doze.
Therefore patients should be monitored carefully for signs and symptoms of infections during and after treatment with canakinumab. 
Stoga kod bolesnika valja pozorno pratiti moguću pojavu znakova i simptoma infekcije tijekom i nakon liječenja kanakinumabom.
If you stop using Ilaris 
Ako prestanete primjenjivati Ilaris
2 In gouty arthritis 
2 Kod uričnog artritisa
Hypersensitivity reactions with canakinumab therapy have been reported. 
Zabilježene su reakcije preosjetljivosti tijekom terapije kanakinumabom.
The recommended dose of Ilaris for adult gouty arthritis patients is 150 mg given as a single dose at the time of a gouty arthritis attack. 
Preporučena doza Ilarisa za odrasle bolesnike s uričnim artritisom je 150 mg i daje se kao jednokratna doza u vrijeme napada uričnog artritisa.
An additional pharmacokinetics analysis showed that the pharmacokinetics of canakinumab in 6 paediatric CAPS patients under the age of 2 years were similar to the pharmacokinetics in paediatric patients 2-4 years of age. 
Dodatna farmakokinetička analiza pokazala je da je farmakokinetika kanakinumaba u 6 pedijatrijskih bolesnika s CAPS-om mlađih od 2 godine bila slična farmakokinetici u pedijatrijskih bolesnika u dobi od 2-4 godine.
Injecting Ilaris yourself or injecting a patient with Ilaris If you are a patient with CAPS, TRAPS, HIDS/MKD, FMF or Still's disease (AOSD or SJIA), or a caregiver of a patient with one of these conditions, you may administer Ilaris injections yourself after proper training in the correct injection technique. 
Ako sami sebi ili bolesniku dajete injekciju Ilarisa Ako ste bolesnik koji ima CAPS, TRAPS, HIDS/MKD, FMF ili Stillovu bolest (SBOD ili SJIA), ili osoba koja njeguje bolesnika s jednim od navedenih stanja, možete sami primijeniti injekcije Ilarisa nakon odgovarajuće obuke iz pravilne tehnike davanja injekcije.
Peak concentrations of canakinumab occurred between 2 to 7 days (Tmax) following single subcutaneous administration of canakinumab 150 mg or 2 mg/kg in paediatric patients 4 years of age and older. 
Vršne koncentracije kanakinumaba javile su se između 2 do 7 dana (Tmax) nakon jednokratne supkutane primjene kanakinumaba 150 mg ili 2 mg/kg kod pedijatrijskih bolesnika u dobi od 4 godine i više.
Phase III trial, pivotal, randomised placebo-controlled treatment period (Part II) Canakinumab n/N (%) 
Ispitivanje faze III, ključno, randomizirano, placebom kontrolirano razdoblje liječenja (II. dio) Kanakinumab n/N (%)
Remove the withdrawal needle from the syringe and place it in the sharps container. 
Maknite iglu za izvlačenje sa štrcaljke i odložite ju u spremnik za oštre predmete.
The primary efficacy endpoint of the randomised treatment period (Part II) was the proportion of responders within each cohort who had resolution of their index disease flare at day 15 and did not experience a new flare during the remainder of the 16-week treatment period (defined as complete response). 
Primarna mjera djelotvornosti u randomiziranom razdoblju liječenja (II. dio) bila je udio bolesnika s odgovorom u svakoj kohorti u kojih se povuklo razbuktavanje osnovne bolesti do 15. dana i u kojih nije došlo do ponovnog razbuktavanja tijekom ostatka 16-tjednog razdoblja liječenja (definirano kao potpuni odgovor).
Slowly inject the water into the vial containing the Ilaris powder. 
Polako ubrizgajte vodu u bočicu s Ilaris praškom.
Bioavailability in gouty arthritis patients has not been determined independently. 
Bioraspoloživost kod bolesnika s uričnim artritisom nije još neovisno utvrđena.
This is administered every eight weeks as a single dose via subcutaneous injection. 
Jedna doza se primjenjuje svakih osam tjedana kao supkutana injekcija.
Mean exposure in a typical gouty arthritis patient (93 kg) after a single subcutaneous 150 mg dose (Cmax: 10.8 µg/ml and AUCinf: 495 µg*d/ml) was lower than in a typical 70 kg CAPS patient (15.9 µg/ml and 708 µg*d/ml). 
Srednja izloženost kod tipičnog bolesnika s uričnim artritisom (93 kg) nakon jednokratne supkutane doze od 150 mg (Cmax: 10,8 µg/ml i AUCinf: 495 µg*d/ml) bila je niža nego kod tipičnog bolesnika s CAPS-om težine od 70 kg (15,9 µg/ml i 708 µg*d/ml).
Open the wrapper containing the injection needle and attach the needle to the syringe. 
Otvorite omot koji sadrži iglu za injekciju i pričvrstite iglu na štrcaljku.
The expected accumulation ratio was 1.3-fold following 6 months of subcutaneous administration of 150 mg canakinumab every 8 weeks. 
Očekivani omjer akumulacije bio je 1,3 puta veći nakon 6 mjeseci supkutane primjene 150 mg kanakinumaba svakih 8 tjedana.
If you see bubbles in the syringe, remove bubbles as instructed by your healthcare professional or pharmacist. 
Ako vidite mjehuriće u štrcaljki, uklonite mjehuriće prema uputama zdravstvenog radnika ili ljekarnika.
Hypersensitivity reactions have been reported in patients treated with canakinumab (see sections 4.3 and 4.4). 
Kod bolesnika liječenih kanakinumabom zabilježene su reakcije preosjetljivosti (vidjeti dio 4.3 i 4.4).
If you forget to use Ilaris 
Ako ste zaboravili primijeniti Ilaris
Gather together the necessary items Included in the pack - one vial of Ilaris solution for injection (keep refrigerated) 
Prikupite potrebne predmete Uključeno u pakiranje jedna bočica Ilaris otopine za injekciju (čuvati u hladnjaku)
Canakinumab should be used as an on-demand therapy to treat gouty arthritis attacks. 
Kanakinumab se treba primjenjivati kao terapija u slučaju pojave simptoma za liječenje napada uričnog artritisa.
• 2 mg/kg for patients who weigh between 7.5 kg and less than 40 kg 
• 2 mg/kg za bolesnike tjelesne težine između 7,5 kg i manje od 40 kg
Insert the needle all the way into the vial until it reaches the bottom edge. 
Gurnite iglu do kraja u bočicu dok ne dođe do dna.
If a satisfactory clinical response has not been achieved 7 days after this increased dose, a third dose of canakinumab at 300 mg or 4 mg/kg can be considered. 
Ako se zadovoljavajući klinički odgovor ne postigne 7 dana nakon te povećane doze, može se razmotriti treća doza kanakinumaba od 300 mg ili 4 mg/kg.
Solution for injection in a vial (type I glass) with a stopper (laminated chlorobutyl rubber) and flip-off cap (aluminium). 
Otopina za injekciju u bočici (staklo tipa I) s čepom (laminirana klorobutilna guma) i flip-off kapicom (aluminij).
By blocking the activity of IL-1 beta, Ilaris may lead to an improvement in these symptoms. 
Blokiranjem aktivnosti IL-1 beta Ilaris može dovesti do poboljšanja tih simptoma.
The recommended dose of canakinumab for adult patients with gouty arthritis is 150 mg administered subcutaneously as a single dose during an attack. 
Preporučena doza kanakinumaba za odrasle bolesnike s uričnim artritisom je 150 mg i primjenjuje se supkutano kao jednokratna doza tijekom napada.
Packs containing 1 vial. 
Pakiranja koja sadrže 1 bočicu.
Set the syringe aside. 
Štrcaljku stavite sa strane.
• Neonatal-onset multisystem inflammatory disease (NOMID), also called chronic infantile neurological, cutaneous, articular syndrome (CINCA), 
• Neonatalna multisistemska upalna bolest, koja se naziva i kroničnim infantilnim neurokutanim artikularnim sindromom,
Instructions for use of Ilaris powder for solution for injection 
Upute za uporabu Ilaris praška za otopinu za injekciju
Keep the sharps container out of reach of children. 
Čuvajte spremnik za oštre predmete izvan dohvata djece.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. 
Unutar svake skupine učestalosti nuspojave su prikazane od najozbiljnijih prema manje ozbiljnima.
TRAPS, HIDS/MKD and FMF patients with body weight  7.5 kg and ≤ 40 kg 
TRAPS, HIDS/MKD i FMF u bolesnika tjelesne težine 7,5 kg i ≤40 kg
The recommended dose of canakinumab for patients with Still's disease (AOSD and SJIA) with body weight ≥ 7.5 kg is 4 mg/kg (up to a maximum of 300 mg) administered every four weeks via subcutaneous injection. 
Preporučena doza kanakinumaba za oboljele od Stillove bolesti (SBOD i SJIA) s tjelesnom težinom ≥ 7,5 kg je 4 mg/kg (do najviše 300 mg) koji se primjenjuju svaka četiri tjedna supkutanom injekcijom.
For patients with a starting dose of 150 mg or 2 mg/kg, if a satisfactory clinical response (resolution of rash and other generalised inflammatory symptoms) has not been achieved 7 days after treatment start, a second dose of canakinumab at 150 mg or 2 mg/kg can be considered. 
Za bolesnike s početnom dozom od 150 mg ili 2 mg/kg, ako se zadovoljavajući klinički odgovor (povlačenje osipa i drugih generaliziranih upalnih simptoma) ne postigne nakon 7 dana od početka liječenja, može se razmotriti druga doza kanakinumaba od 150 mg ili 2 mg/kg.
Ilaris is indicated for the treatment of active Still's disease including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. 
Ilaris je indiciran za liječenje aktivne Stillove bolesti uključujući Stillovu bolest odrasle dobi (SBOD) i sistemski juvenilni idiopatski artritis (SJIA) u bolesnika u dobi od 2 i više godina koji nisu imali primjereni odgovor na prethodnu terapiju nesteroidnim protuupalnim lijekovima (NSAIL) i sistemskim kortikosteroidima.
What Ilaris looks like and contents of the pack Ilaris is supplied as a powder for solution for injection (150 mg in a 6 ml glass vial). 
Ilaris se isporučuje kao prašak za otopinu za injekciju (150 mg u staklenoj bočici od 6 ml).
All up-titrated patients remained at the increased dose of 300 mg (or 4 mg/kg for patients ≤ 40 kg) every 4 weeks. 
Svi bolesnici kojima je postupno povećana doza ostali su na povećanoj dozi od 300 mg (ili 4 mg/kg za bolesnike ≤40 kg) svaka 4 tjedna.
The recommended dose of Ilaris for patients with Still's disease (AOSD or SJIA) with body weight of 7.5 kg and above is 4 mg/kg (up to a maximum of 300 mg). 
Preporučena doza Ilarisa za bolesnike sa Stillovom bolešću (SBOD ili SJIA) tjelesne težine od 7,5 kg i više je 4 mg/kg (do najviše 300 mg).
Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). 
Familial Mediterranean fever, FMF) Ilaris je indiciran za liječenje obiteljske mediteranske groznice (FMF).
The clinical impact of this is unknown. 
Nije poznato kakav klinički učinak to ima.
If the child responds well enough to this, treatment may be continued with a dose of 8 mg/kg every 8 weeks. 
Ako dijete ima dovoljno dobar odgovor na nju, liječenje se može nastaviti s dozom od 8 mg/kg svakih 8 tjedana.
Dispose of it as directed by your healthcare provider or pharmacist. 
Odložite ga prema uputama zdravstvenog djelatnika ili ljekarnika.
Laboratory abnormalities in gouty arthritis patients Haematology 
Laboratorijske abnormalnosti kod bolesnika s uričnim artritisom Hematologija
Properly dispose of vials containing remaining water and Ilaris solution (if any) as directed by your healthcare provider or pharmacist. 
Pravilno odložite bočice koje sadrže preostalu vodu i Ilaris otopinu (ako je ima) prema uputama zdravstvenog djelatnika ili ljekarnika.
Time to flare: 
Vrijeme do naglog pogoršanja bolesti:
Carefully remove the transfer needle from the vial and recap the needle as instructed by your healthcare provider or pharmacist. 
Pažljivo izvucite iglu za prijenos iz bočice i vratite kapicu na iglu prema uputama koje ste dobili od zdravstvenog djelatnika ili ljekarnika.
Tap the side of the vial to remove any residual liquid from the stopper. 
Lagano kucnite bočicu sa strane kako biste uklonili ostatak tekućine sa čepa.
For patients with a starting dose of 4 mg/kg, if a satisfactory clinical response has not been achieved 7 days after treatment start, a second dose of canakinumab 4 mg/kg can be considered. 
Za bolesnike s početnom dozom od 4 mg/kg, ako se zadovoljavajući klinički odgovor ne postigne 7 dana nakon početka liječenja, može se razmotriti druga doza kanakinumaba od 4 mg/kg.
If you have CAPS, TRAPS, HIDS/MKD, FMF or Still's disease (AOSD or SJIA) and have forgotten to inject a dose of Ilaris, inject the next dose as soon as you remember. 
Ako imate CAPS, TRAPS, HIDS/MKD, FMF ili Stillovu bolest (SBOD ili SJIA) i zaboravili ste ubrizgati dozu Ilarisa, ubrizgajte sljedeću dozu čim se sjetite.
Based on the population pharmacokinetic modelling analysis, the pharmacokinetics of canakinumab in children aged 2 to < 4 years were similar to those in patients 4 years of age and older. 
Na temelju analize populacijskog farmakokinetičkog modeliranja, farmakokinetika kanakinumaba kod djece u dobi od 2 do <4 godine bila je slična onoj kod bolesnika u dobi od 4 i više godina.
In study G2305, the Childhood Health Assessment Questionnaire Least Squares means improvement was 0.69 for canakinumab vs placebo representing 3.6 times the minimal clinically important difference of 0.19 (p=0.0002). 
Childhood Health Assessment Questionnaire) izračunato metodom najmanjih kvadrata bilo je 0,69 za kanakinumab u odnosu na placebo, što predstavlja vrijednost 3,6 puta veću od najmanje klinički važne razlike od 0,19 (p=0,0002).
Ilaris can be used together with colchicine, if appropriate. 
Ilaris se može koristiti zajedno s kolhicinom, kada je primjereno.
Concomitant treatment with ULTs was reported by 42% of patients at entry. 
Istodobno liječenje lijekovima za snižavanje urata (ULT) bilo je zabilježeno kod 42% bolesnika prilikom uključivanja u ispitivanje.
The expected accumulation ratio was 1.1-fold following subcutaneous administration of 150 mg canakinumab every 12 weeks. 
Očekivani omjer akumulacije bio je 1,1 puta veći nakon supkutane primjene 150 mg kanakinumaba svakih 12 tjedana.
Table 3 Tabulated summary of efficacy in Phase III trial, pivotal, randomised, placebocontrolled treatment period (Part II) 
Tablica 3 Tablični sažetak djelotvornosti u ispitivanju faze III, ključnom, randomiziranom, placebom kontroliranom razdoblju liječenja (II. dio)
Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD). 
D syndrome, HIDS)/nedostatak mevalonat kinaze (engl. mevalonate kinase deficiency, MKD) Ilaris je indiciran za liječenje sindroma hiperimunoglobulina D (HIDS)/nedostatka mevalonat kinaze (MKD).
TRAPS, HIDS/MKD and FMF patients with body weight > 40 kg 
TRAPS, HIDS/MKD i FMF u bolesnika tjelesne težine >40 kg
- Part III: Patients who completed 16 weeks of treatment and were classified as responders were re-randomised into a 24-week, double-blind withdrawal period during which they received canakinumab 150 mg (2 mg/kg for patients ≤ 40 kg) s.c. or placebo every 8 weeks. 
- III. dio: bolesnici koji su dovršili 16 tjedana liječenja i kategorizirani su kao bolesnici s odgovorom ponovno su bili randomizirani u 24-tjedno, dvostruko slijepo razdoblje ustezanja tijekom kojeg su primali kanakinumab 150 mg (2 mg/kg za bolesnike ≤40 kg) s.c. ili placebo svakih 8 tjedana.
The solution should be colourless or may have a slight brownish-yellow tint. 
Otopina mora biti bezbojna ili imati blago smećkasto-žutu nijansu.
CAPS, TRAPS, HIDS/MKD, FMF or Still's disease (AOSD or SJIA): You should continue using Ilaris for as long as the doctor tells you. 
CAPS, TRAPS, HIDS/MKD, FMF ili Stillova bolest (SBOD ili SJIA): trebate nastaviti primjenjivati Ilaris dokle god Vam to liječnik kaže.
UNIT PACK CARTON 
KUTIJA JEDINIČNOG PAKIRANJA
Powder for solution for injection in a vial (type I glass) with a stopper (coated chlorobutyl rubber) and flip-off cap (aluminium). 
Prašak za otopinu za injekciju u bočici (staklo tipa I) s čepom (obložena klorobutilna guma) i flip-off kapicom (aluminij).
Keep the needle all the way in the skin while slowly pushing the syringe plunger down until the barrel is empty. 
Držite iglu do kraja u koži i lagano potiskujte klip štrcaljke prema dolje dok se tijelo štrcaljke ne isprazni.
Bioavailability in SJIA patients has not been determined independently. 
Bioraspoloživost u bolesnika sa SJIA-om nije još neovisno utvrđena.
- Put the withdrawal needle on the syringe. 
- Stavite iglu za izvlačenje na štrcaljku.